Q-omics provides the consensus-scored GUSBP11 profile across patient tissues and cancer cell-line models. GUSBP11 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GUSBP11 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, GUSBP11 RNA expression shows 18,466 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, LIHC, and UVM as cancer lineages where GUSBP11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GUSBP11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GUSBP11 survival associations across molecular data types. GUSBP11 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GUSBP11 RNA expression–survival associations across cancer types. High GUSBP11 expression shows unfavorable associations in ACC, LIHC and KICH, but favorable associations in BLCA, SKCM and THCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GUSBP11 RNA expression.
This table summarizes GUSBP11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for GUSBP11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GUSBP11 shows lower tumor expression in BRCA and KICH and higher tumor expression in LIHC, THCA, CHOL and KIRC. The LIHC box plot shows higher GUSBP11 RNA expression in tumor versus normal tissue (log2 FC = +0.349, t-test p < 0.001).
This table shows molecular features associated with GUSBP11 in patient tissues and cancer cell lines. In patient samples, GUSBP11 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GUSBP11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BONE.
